The company has not filed an annual or quarterly report since its Q1 FY2024 10-Q, filed May 23, 2024. Its latest SEC filing is a 15-12G from May 24, 2024.
10-Q for Q1 FY2024, filed May 23, 2024
The sections below describe the company as of the FY2023 annual report.
Sells Omisirge, a donor-cell therapy for stem cell transplants, to transplant centers treating patients with blood cancers.
10-K for FY2023, filed Mar 27, 2024
U.S. transplant centers buy Omisirge through the company’s sole U.S. distributor, and payment is tied to delivery of the product to the transplant center.
$1.8M
10-K for FY2023, filed Mar 27, 2024
$1.8M ↗
The company sells Omisirge to a sole U.S. distributor, which is its customer.
10-K for FY2023, filed Mar 27, 2024The Company’s revenues are comprised of product revenue which represents the sales of Omisirge. The Company has a sole distributor in the…View ↗
No. It lost $63M in FY2023.
8-K, filed May 24, 2024
On May 13, 2024, the Subsidiary filed a voluntary petition in the U.S. Court seeking relief under Chapter 11 of Title 11 of the Bankruptcy…View ↗
8-K, filed Apr 22, 2024
On April 22, 2024, Abigail Jenkins, solely in her capacity as a duly authorized foreign representative (the “Foreign Representative”) of…View ↗
Commercial product
The latest report describes Omisirge as an FDA-approved product being commercialized, whereas the older report described omidubicel as an investigational product candidate and planned to seek FDA approval.
20-F for FY2020, filed Mar 9, 2021 10-K for FY2023, filed Mar 27, 2024Our most advanced product candidate, omidubicel, is an investigational advanced cell therapy designed to expand the life-saving benefits of…View ↗
Pipeline narrowed
The older report described an NK cell therapy as a development candidate and planned to expand the pipeline; the latest report says work on preclinical NK programs was terminated and focuses on commercializing Omisirge.
20-F for FY2020, filed Mar 9, 2021 10-K for FY2023, filed Mar 27, 2024
Loading...
